摘要
目的分析阿德福韦酯联合拉米夫定治疗乙型肝炎(乙肝)肝硬化失代偿期的疗效。方法 80例乙肝肝硬化失代偿期患者,将其随机分为对照组和治疗组,各40例,两组患者均实行保肝、利尿等基础治疗,对照组患者在实行基础治疗的同时服用拉米夫定,而治疗组则在基础治疗的同时服用阿德福韦酯和拉米夫定。观察治疗3个月后两组的肝功能和出凝血时间变化情况。结果两组患者经过治疗后,肝功能和出凝血时间均得到有效改善,同时治疗组的疗效明显优于对照组(P<0.05),两组治疗后均未出现不良反应。结论阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿期的疗效显著,安全可靠,值得进一步推广应用。
Objective To analyze curative effect by adefovir dipivoxil and lamivudine in the treatment of decompensated hepatitis B cirrhosis period. Methods A total of 80 patients with decompensated hepatitis B cirrhosis period were randomly divided into control group and treatment group, with 40 cases in each group. Both groups received basic treatment of liver protection and dieresis, and the control group received additional lamivudine, while the treatment group received additional combination of adefovir dipivoxil and lamivudine. Changes of liver function and bleeding and coagulation time of the two groups were observed after 3 months of treatment. Results Both groups had effectively improved liver function and bleeding and coagulation time after treatment. The treatment group had much better curative effect than the control group（P0.05）. There was no adverse reactions in both groups after treatment. Conclusion Combination of adefovir dipivoxil and lamivudine provides remarkable curative effect in treating decompensated hepatitis B cirrhosis period. This method is safe and reliable, and it is worthy of further promotion and application.
出处
《中国实用医药》
2015年第20期26-27,共2页
China Practical Medicine
关键词
乙型肝炎
肝硬化失代偿期
阿德福韦酯
拉米夫定
Hepatitis B
Decompensated cirrhosis period
Adefovir dipivoxil
Lamivudine
